Shaw has experience providing commercial, financial, strategic, medical and operations leadership across the biopharmaceutical industry.
She currently serves as senior vice president of Eli Lilly and Co., and president of Lilly Bio-Medicines.
Shaw also serves as a board member of both Avantor, Inc. and the biotechnology Industry Organization, and as an advisor to the Healthcare Businesswomen's Association.
Prior to joining Lilly, Shaw most recently served as US Country Head and president of Novartis Corp. and North American Head of Novartis Oncology.
She earned a BA in Business Administration from Iowa State University and an MBA from the University of Wisconsin.
Kite, a Gilead company, is a biopharmaceutical company based in Santa Monica, California. Kite is engaged in the development of innovative cancer immunotherapies.
The company is focused on chimeric antigen receptor and T cell receptor engineered cell therapies.
Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need.
The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients